Description: 

Noninvasive ventilation (NIV) or the delivery of positive pressure ventilation delivered through a noninvasive interface has become more common as its benefits are increasingly recognized. NIV has proven efficacy for hypercapnic respiratory failure, especially that due to COPD exacerbations. High-flow nasal cannula (HFNO) comprises an air/oxygen blender, an active humidifier, a single heated circuit, and a nasal cannula. HFNO has shown promise to treat hypoxic respiratory failure. This webinar will explore a new strategy in the treatment of respiratory conditions. Specifically, this presentation will discuss how HFNO may play a useful complementary role during breaks from NIV.

 

Learning Objectives:

Upon completion of this activity, the participant will be able to:

Discuss indications for NIV and HFNO

Compare and contrast physiologic actions of NIV and HFNO

Demonstrate how HFNO and NIV can work in complementary fashion

 

Bio:

Nicholas S Hill, MD, is Professor of Medicine at Tufts University School of Medicine, and Chief of the Pulmonary & Critical Care and Sleep Division at Tufts Medical Center in Boston, MA. His primary research interests include the role of angiogenic factors in pulmonary vascular biology, therapeutic approaches for clinical pulmonary hypertension, and evaluating ways of delivering and testing the efficacy of noninvasive ventilation. Dr Hill has authored or coauthored more than 200 articles in peer-reviewed journals such as American Journal of Physiology, Respiratory Medicine, and Critical Care Medicine. He is a member of the American College of Chest Physicians, American Thoracic Society (also past president), American Association for the Advancement of Science, and Pulmonary Hypertension Association.